ADMA Biologics Inc (NASDAQ:ADMA)
| 3.85 Delayed Data As of 4:00pm ET |  +0.14 / +3.77%Today’s Change | 1.38 Today|||52-Week Range 3.98 | -0.77% Year-to-Date |
Latest ADMA News | Press Releases
| Sage and Biogen's NDA for Depression Drug Gets Priority Review 10:17am / Zacks.com - Paid Partner Content | Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates Feb 03 / Zacks.com - Paid Partner Content |
| Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod Feb 06 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 3.71 |
| Today’s open | 3.68 |
| Day’s range | 3.66 - 3.87 |
| Volume | 165,709 |
| Average volume (3 months) | 3,136,464 |
| Market cap | $818.8M |
Data as of 4:00pm ET, 02/07/2023
Growth & Valuation
| Earnings growth (last year) | +41.62% |
| Earnings growth (this year) | +36.76% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +91.72% |
| P/E ratio | NM |
| Price/Sales | 2.43 |
| Price/Book | 5.22 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALECAlector Inc | +0.13 | +1.35% |
| ---- | ||
| ANIPANI Pharmaceuticals ... | +0.67 | +1.49% |
| BCYCBicycle Therapeutics... | +0.71 | +2.51% |
Data as of 3:59pm ET, 02/07/2023
Financials
| Next reporting date | March 16, 2023 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $80.9M |
| Annual profit (last year) | -$71.6M |
| Net profit margin | -88.52% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Ramsey, New Jersey |
Forecasts
